Literature DB >> 1307218

Increased risk of bacterial endocarditis in inflammatory bowel disease.

G Kreuzpaintner1, D Horstkotte, A Heyll, B Lösse, G Strohmeyer.   

Abstract

PURPOSE: The purpose of this retrospective as well as prospective case-control study was to analyze a possible overrepresentation of inflammatory bowel diseases among patients with native valve endocarditis as well as the factors that predispose patients with inflammatory bowel disease to infective endocarditis. PATIENTS AND METHODS: Among 213 consecutive patients treated for proven native valve endocarditis, six (2.8%) had inflammatory bowel diseases (three with ulcerative colitis and three with Crohn's disease). Three patients with inflammatory bowel disease were from the retrospective group, and three were from the prospective group. The prevalence of inflammatory bowel diseases has been determined to be 0.0641% in the Düsseldorf area.
RESULTS: On the basis of these data, a 44-fold overrepresentation of inflammatory bowel diseases among the 213 patients with endocarditis was calculated with a statistical significance of p much less than 0.001.
CONCLUSIONS: Inflammatory bowel disease may be considered an independent risk factor for bacterial endocarditis. Reasons may be more frequent bacteremias as a result of the higher incidence of diagnostic and therapeutic interventions, as well as increased permeability of the damaged mucosa for bacteria and the therapeutic immunosuppression in patients with active inflammatory bowel disease. Prophylaxis for bacterial endocarditis should be carefully considered before expected bacteremias in patients with highly active inflammatory bowel disease even in the absence of cardiac factors predisposing to bacterial endocarditis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1307218     DOI: 10.1016/0002-9343(92)90269-h

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  7 in total

1.  Burkholderia ginsengisoli bacteraemia: emergence of a novel pathogen.

Authors:  Laura R Marks; Hema Dodd; Thomas A Russo; Charles S Berenson
Journal:  BMJ Case Rep       Date:  2016-02-24

2.  IFN-γ drives inflammatory bowel disease pathogenesis through VE-cadherin-directed vascular barrier disruption.

Authors:  Victoria Langer; Eugenia Vivi; Daniela Regensburger; Thomas H Winkler; Maximilian J Waldner; Timo Rath; Benjamin Schmid; Lisa Skottke; Somin Lee; Noo Li Jeon; Thomas Wohlfahrt; Viktoria Kramer; Philipp Tripal; Michael Schumann; Stephan Kersting; Claudia Handtrack; Carol I Geppert; Karina Suchowski; Ralf H Adams; Christoph Becker; Andreas Ramming; Elisabeth Naschberger; Nathalie Britzen-Laurent; Michael Stürzl
Journal:  J Clin Invest       Date:  2019-11-01       Impact factor: 14.808

3.  Additional Candida albicans administration enhances the severity of dextran sulfate solution induced colitis mouse model through leaky gut-enhanced systemic inflammation and gut-dysbiosis but attenuated by Lactobacillus rhamnosus L34.

Authors:  Wimonrat Panpetch; Pratsanee Hiengrach; Sumanee Nilgate; Somying Tumwasorn; Naraporn Somboonna; Alisa Wilantho; Piraya Chatthanathon; Piyapan Prueksapanich; Asada Leelahavanichkul
Journal:  Gut Microbes       Date:  2019-09-18

4.  [Infective endocarditis].

Authors:  D Horstkotte; C Piper
Journal:  Herz       Date:  2015-04       Impact factor: 1.443

5.  Overexpression of alpha(1)-acid glycoprotein in transgenic mice leads to sensitisation to acute colitis.

Authors:  T Hochepied; A Wullaert; F G Berger; H Baumann; P Brouckaert; L Steidler; C Libert
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

Review 6.  Neurologic manifestations of gastrointestinal and liver diseases.

Authors:  José M Ferro; Sofia Oliveira
Journal:  Curr Neurol Neurosci Rep       Date:  2014-10       Impact factor: 5.081

Review 7.  Cardiovascular Manifestations of Inflammatory Bowel Disease: Pathogenesis, Diagnosis, and Preventive Strategies.

Authors:  Diana-Maria Bunu; Cristian-Eugen Timofte; Manuela Ciocoiu; Mariana Floria; Claudia-Cristina Tarniceriu; Oana-Bogdana Barboi; Daniela-Maria Tanase
Journal:  Gastroenterol Res Pract       Date:  2019-01-13       Impact factor: 2.260

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.